Biolegend, 317435, Brilliant Violet 650™ anti-human CD4 Antibody, 25tests

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16.
25tests
Verified Reactivity: Human, Cynomolgus, Rhesus
Reported Reactivity: Chimpanzee
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Human peripheral T cells
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 650™ under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. Brilliant Violet 650™ excites at 405 nm and emits at 645 nm. The bandpass filter 660/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 650™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454). In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.9
Application References(PubMed link indicates BioLegend citation): Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36. Linder J, et al. 1987. Am. J. Pathol. 127:1. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC) Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen) Lederman S, et al. 1991. Mol Immunol. 28:1171-81.
Product Citations: Korniotis S, et al. 2022. J Cell Sci. 135:. PubMed Baharlou H, et al. 2022. Cell Rep. 40:111385. PubMed Loh L, et al. 2016. Proc Natl Acad Sci U S A. 113: 10133 - 10138. PubMed Mylvaganam G, et al. 2014. J Immunol. 193:4527. PubMed Klemm F, et al. 2020. Cell. 181(7):1643-1660.e17. PubMed Pino M, et al. 2022. Nat Commun. 13:5055. PubMed Calascibetta F, et al. 2016. J Virol. 90: 7541 - 7551. PubMed Pauthner MG, et al. 2019. Immunity. 50:241. PubMed Cartwright E, et al. 2014. J Immunol. 192:4666. PubMed Huang B, et al. 2020. Cell. 179(5):1160-1176.e24.. PubMed Ollé Hurtado M, et al. 2019. PLoS One. 14:e0216373. PubMed Silva M, et al. 2021. Sci Immunol. 6:eabf1152. PubMed Harper J, et al. 2022. J Clin Invest. . PubMed Boyle M, et al. 2015. J Infect Dis. 212: 416-425. PubMed Jagannathan P, et al. 2017. Sci Rep. 10.1038/s41598-017-10624-3. PubMed Jacob V, et al. 2017. Inflamm Bowel Dis. 23:903. PubMed Rodda LB, et al. 2020. Cell. 184(1):169-183.e17. PubMed Kuebler P, et al. 2015. Proc Natl Acad Sci U S A. 112: 8379 - 8384. PubMed Wood MP, et al. 2020. J Infect Dis. 222:44. PubMed Buggert M, et al. 2014. J Immunol. 192:2099. PubMed Harper JL, et al. 2020. Nat Med. 519:26. PubMed Neal JT, et al. 2018. Cell. 175:1972. PubMed Del Alcazar D, et al. 2019. Cell Rep. 28:3047. PubMed Peluso MJ, et al. 2021. Cell Rep. 36:109518. PubMed de Jonge K, et al. 2021. OncoImmunology. 10(1):1873585. PubMed Dan J, et al. 2016. J Immunol. 197: 983 - 993. PubMed Cirelli KM et al. 2019. Cell. 177(5):1153-1171 . PubMed Magagna I, et al. 2021. Cancers (Basel). 13:. PubMed Céspedes PF, et al. 2022. Nat Commun. 13:3460. PubMed Li D, et al. 2020. Immunohorizons. 0.661805556. PubMed Noto A, et al. 2013. J Vis Exp. 82: 51105. PubMed Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed FitzPatrick MEB, et al. 2021. Cell Rep. 34:108661. PubMed Kim Y, et al. 2021. Oncol Lett. 1.022222222. PubMed Maas RR, et al. 2021. Nat Protoc. 16:4692. PubMed Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed
RRID: AB_11149170 (BioLegend Cat. No. 317435) AB_2563050 (BioLegend Cat. No. 317436)
Structure: Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution: T cell subset, majority of thymocytes, monocytes/macrophages
Function: MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor: MHC class II molecules, HIV gp120, IL-16
Cell Type: Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area: Immunology
Molecular Family: CD Molecules
Antigen References: 1. Center D, et al. 1996. Immunol. Today 17:476. 2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.
Gene ID: 920
UniProt: View information about CD4 on UniProt.org
Clone: OKT4
Regulatory Status: RUO
Workshop: HCDM listed
Other Names: T4
Isotype: Mouse IgG2b, κ
Q: I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
A: TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.